Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
The grant is designated for the research and development of Pyronaridine
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
e brings over 27+ years of rich pharmaceutical experience
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Subscribe To Our Newsletter & Stay Updated
